Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Net Income From Continuing Operations : HK$3,959 Mil (TTM As of Mar. 2025)

View and export this data going back to 2012. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Shanghai Fosun Pharmaceutical (Group) Co's net income from continuing operations for the three months ended in Mar. 2025 was HK$1,010 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was HK$3,959 Mil.

Shanghai Fosun Pharmaceutical (Group) Co Net Income From Continuing Operations Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Net Income From Continuing Operations Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

4,670.58

6,093.28

4,408.19

3,166.56

3,750.13

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															854.07	821.95	1,066.68	1,061.18	1,009.56

Shanghai Fosun Pharmaceutical (Group) Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$3,959 Mil.

Shanghai Fosun Pharmaceutical (Group) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (HKSE:02196) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

SFOSF:USA 08HH:Germany 08HH:Germany 600196:China

Address

No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233

Website

https://www.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.

Executives

Blackrock, Inc.	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Shanghai Fosun High Technology (group) Co., Ltd.
Fosun International Holdings Ltd.	2201 Interest of corporation controlled by you
Fosun International Limited	2101 Beneficial owner
Guo Guangchang	2201 Interest of corporation controlled by you

Shanghai Fosun Pharmaceutical (Group) Co Headlines

No Headlines